retatrutide lilly The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli still in Phase II trials. While early studies have shown promising weight-loss results, Eli Lilly's Next-Gen Obesity Drug

Review the sources used below for this article: This article references information from a study published in the BMJ: Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation

Examples from customer stories include working professionals who appreciate appetite control during long hours, parents who manage cravings while balancing their busy schedules, and older adults who notice improved digestion and steady energy levels

They are also contraindicated in those with personal or family history of medullary thyroid carcinoma and those with multiple endocrine neoplasia type 2

A coach can help you develop strategies to manage your appetite and troubleshoot challenges as they arise

For a detailed comparison of semaglutide versus tirzepatide beyond side effects, including efficacy, dosing, and weight loss data, our dedicated comparison page covers the full picture